Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Clinical Study of GnP Regimen (Nab-paclitaxel + Gemcitabine) Combined With Serplulimab and Stereotactic Body Radiation Therapy (SBRT) as First-line Treatment for Locally Advanced Pancreatic Cancer

NCT07101679 is registered in ClinicalTrials.gov with West China Hospital as lead sponsor.

NCT NCT07101679
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07101679 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Clinical Study of GnP Regimen (Nab-paclitaxel + Gemcitabine) Combined With Serplulimab and Stereotactic Body Radiation Therapy (SBRT) as First-line Treatment for Locally Advanced Pancreatic Cancer
Lead sponsor
West China Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
April 16, 2025
Completion date
April 15, 2029
Enrollment
23 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced pancreatic ductal adenocarcinoma